ArticleApplied spectroscopy2022
Group and Basis Restricted Non-Negative Matrix Factorization and Random Forest for Molecular Histotype Classification and Raman Biomarker Monitoring in Breast Cancer.
Article in Applied spectroscopy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 17 citations in OpenAlex.
- Surface-Enhanced Raman Spectroscopy for Biomedical Applications: Recent Advances and Future Challenges.ACS applied materials & interfaces · 2025Review
- Raman spectroscopy and convolutional neural networks for monitoring biochemical radiation response in breast tumour xenografts.Scientific reports · 2023Article
- A Machine Learning Framework for Detecting COVID-19 Infection Using Surface-Enhanced Raman Scattering.Biosensors · 2022Article
- Nanotube abundance from non-negative matrix factorization of Raman spectra as an example of chemical purity from open source machine learning.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Raman spectroscopy is a non-invasive optical technique that can be used to investigate biochemical information embedded in cells and tissues exposed to ionizing radiation used in cancer therapy. Raman spectroscopy could potentially be incorporated in personalized radiation treatment design as a tool to monitor radiation response in at the metabolic level. However, tracking biochemical dynamics remains challenging for Raman spectroscopy. Here we developed a novel analytical framework by combining group and basis restricted non-negative matrix factorization and random forest (GBR-NMF-RF). This framework can monitor radiation response profiles in different molecular histotypes and biochemical dynamics in irradiated breast cancer cells. Five subtypes of; human breast cancer (MCF-7, BT-474, MDA-MB-230, and SK-BR-3) and normal cells derived from human breast tissue (MCF10A) which had been exposed to ionizing radiation were tested in this framework. Reference Raman spectra of 20 biochemicals were collected and used as the constrained Raman biomarkers in the GBR-NMF-RF framework. We obtained scores for individual biochemicals corresponding to the contribution of each Raman reference spectrum to each spectrum obtained from the five cell types. A random forest classifier was then fitted to the chemical scores for performing molecular histotype classifications (HER2, PR, ER, Ki67, and cancer versus non-cancer) and assessing the importance of the Raman biochemical basis spectra for each classification test. Overall, the GBR-NMF-RF framework yields classification results with high accuracy (>97%), high sensitivity (>97%), and high specificity (>97%). Variable importance calculated in the random forest model indicated high contributions from glycogen and lipids (cholesterol, phosphatidylserine, and stearic acid) in molecular histotype classifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.